Yokohama, Japan

Takashi Shomura


Average Co-Inventor Count = 6.8

ph-index = 6

Forward Citations = 155(Granted Patents)


Location History:

  • Yokohama, JA (1976 - 1978)
  • Kanagawa, JP (1984 - 1992)
  • Yokohama, JP (1978 - 1993)

Company Filing History:


Years Active: 1976-1993

Loading Chart...
29 patents (USPTO):Explore Patents

Title: Takashi Shomura: Innovator in Pharmaceutical Advancements

Introduction

Takashi Shomura is a prominent inventor based in Yokohama, Japan, known for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 29 patents, Shomura's work has been vital in advancing medical treatments and understanding drug interactions.

Latest Patents

Among Shomura's latest innovations are the 2,3-disubstituted-4-hydroxyquinoline derivatives. These compounds represent a general formula designed to exhibit strong antagonistic action on leukotriene D4, potentially benefiting a wide range of therapeutic applications. Additionally, he has developed a novel substance known as PF 1022, which has shown promise in treating helminthic parasitic infections. This substance is produced by cultivating a specific fungal strain capable of generating the compound, highlighting the innovative methods employed in his research.

Career Highlights

Shomura currently works with Meiji Seika Kaisha, Ltd., where he continues to push the boundaries of pharmaceutical science. His commitment to research and development has not only led to patents but has also inspired further innovations within the company.

Collaborations

In his journey as an inventor, Takashi has collaborated with notable colleagues such as Shigeharu Inouye and Taro Niida. These partnerships have enriched his research endeavors, making significant strides in the field of pharmaceutical inventions.

Conclusion

Takashi Shomura's work exemplifies the critical role of innovation in healthcare, particularly through his patent contributions. His dedication to developing effective treatments showcases the necessity of ongoing research and collaboration in addressing medical challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…